Stockreport

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF Expect to initiate a Phase 1/2a trial in the U.S. in advanced KRAS G12D mutant solid tumors in mid-2025Initial safety and efficacy results from the trial of VS-7375 by p [Read more]